[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635917":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":33,"responsibleParty":48,"collaborators":19,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":19,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":19,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Genentech, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"RO7851624","EXPERIMENTAL","Participants will receive RO7851624 in a dose escalation stage followed by a dose expansion stage.",[13],"Drug: RO7851624",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Participants will receive RO7851624 as per the schedule described in the protocol.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Clinical Trials","Hoffmann-La Roche","STUDY_DIRECTOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Reference Study ID Number: GO46140 https:\u002F\u002Fforpatients.roche.com\u002F","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":32,"role":28,"phone":19,"phoneExt":19,"email":19},"Fastest response: use the inquiry form. No email attachments. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":19},"Peter MacCallum Cancer Center","RECRUITING","Parkville","Victoria","3052","Australia","AU",{"type":43,"coordinates":44},"Point",[45,46],144.95,-37.78333,{"lat":46,"lon":45},{"type":49,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100635917","phase-1-a-study-to-evaluate-ro7851624-in-participants-with-relapsedrefractory-multiple-myeloma-rrmm-100635917",false,"NCT07558915","A Study to Evaluate RO7851624 in Participants With Relapsed\u002FRefractory Multiple Myeloma (RRMM)","An Open-Label, Multicenter, Phase Ia\u002Fb Study Evaluating the Safety and Pharmacokinetics of RO7851624 in Patients With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Life expectancy of at least 12 weeks.\n* Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria.\n* Measurable disease.\n\nExclusion Criteria:\n\n* Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to first dose of study treatment.\n* Autologous stem cell transplant (SCT) with insufficient time prior to first dose of study treatment.\n* Prior allogeneic SCT.\n* Prior solid organ transplantation.","ALL","18 Years",{"count":60,"type":61},160,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1","This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \\[PIs\\], immunomodulators \\[IMiDs\\], and anti-cluster of differentiation 38 \\[anti-CD38\\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.",[67],"Relapsed\u002FRefractory Multiple Myeloma","2026-06-18",{"date":70,"type":71},"2026-06-23","ACTUAL",{"date":70,"type":61},{"date":74,"type":61},"2031-10-01",{"name":5,"class":6},1]